NEW YORK June 20 2017 PRNewswire Immune Pharmaceuticals NASDAQIMNP "Immune" a clinical stage biopharmaceutical company announced today that patient enrollment in a Phase III clinical trial evaluating the safety and efficacy of Ceplene histamine ...
↧